drugset / Trial / NCT02568046
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).
Timeline
- Start
- 2016-03-15
- Primary completion
- 2017-05-15
- Completion
- 2018-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sym004 | Monoclonal antibody | 9 mg/kg | — |
| Subject | Sym004 | Monoclonal antibody | 12 mg/kg | — |
| Background | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |